National and Kapodistrian University of Athens
Ανοσοϊστοχημική μελέτη (ανάδειξη) των υποδοχέων σωματοστατίνης (SSTRs) σε αδενοκαρκινώματα του παχέος εντέρου
Abstract
dc:descriptionColorectal cancer (CRC) is the third most common malignancy in adults and the second leading cause of cancer deaths in men and women combined. Locally advanced and metastatic CRC remains largely incurable, and novel strategies are urgently needed to assess prognosis and guide treatment . Recent studies have shown that procedures that can modify staging, such as the detection of tumour cells inthe systemic circulation, may more accurately guide therapeutic protocols. Somatostatin [somatotropinrelease inhibiting factor (SRIF)] is a cyclic peptide hormone that is widely distributed throughout the human body, including the central nervous andthe gastrointestinal systems . The two main SRIF forms produced in humans are the:SRIF14andSRIF28. Both SRIF isoforms have strongly overlapping biological roles and are capable of binding to the five known, distinct,SRIF receptor subtypes (Sst1to5), which may coexist inthe same tissue and even onthe same cell at different densities . Sst expression has been demonstrated in cell lines and primary tissue samples in a wide range of neuroendocrine and non-neuroendocrine solid tumours, including colon cancer . In addition,SRIF agonists have shown significant antitumour activity against CRC cell lines in vitro as well as in rodent xenograft models . However, clinical data derived from trials utilizing SRIF agonists as monotherapies against nonneuroendocrine solid tumours have, with few exceptions [12,13], shown little benefit with regard to survival, although there is some evidence of an enhanced palliative effect in certain indications. Moreover, it should be mentioned that the antitumour activity of SRIF agonists can be indirectly mediated by the suppression of IGF-I production in serum or inthe tumour microenvironment. TheSRIF agonists currently inthe market show highest affinity to the Sst receptor subtypes 2and5.Sst2andSst5 have previously been reported to be overexpressed in less aggressive tumour phenotypes and have been associated with better survival outcomes in various cancers .In this study, we determined the immunohistochemical expression levels ofSst2andSst5in patients with CRCand investigated their association with clinicopathological parameters and overall survival.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2014
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Evangelou, Ioulia
- Ευαγγέλου, Ιουλία
Subjects
dc:subject × 11Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/42018